Compositions and Methods for Antibodies Targeting Complement Protein C5

Abstract

The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.

1 . A method of treating age related macular degeneration comprising administering to a subject in need thereof an effective amount of a composition comprising an isolated antibody or antigen binding fragment thereof that specifically binds to a human complement C5 protein, said antibody or antigen binding fragment thereof comprising an HCDR1 sequence comprising the sequence of SEQ ID NO: 1, an HCDR2 sequence comprising the sequence of SEQ ID NO: 2, an HCDR3 sequence comprising the sequence of SEQ ID NO: 3, an LCDR1 sequence comprising the sequence of SEQ ID NO: 4, an LCDR2 sequence comprising the sequence of SEQ ID NO: 5, and an LCDR3 sequence comprising the sequence of SEQ ID NO: 6. 
     
     
         2 . The method of  claim 1 , wherein the antibody, or antigen binding fragment, further comprises a heavy chain variable region having 95% sequence identity to SEQ ID NO: 7. 
     
     
         3 . The method of  claim 1 , wherein the antibody, or antigen binding fragment, further comprises a light chain variable region having 95% sequence identity to SEQ ID NO: 8. 
     
     
         4 . The method of  claim 2 , wherein the antibody, or antigen binding fragment, further comprises a light chain variable region having 95% sequence identity to SEQ ID NO: 8. 
     
     
         5 . The method of  claim 1 , wherein the antibody, or antigen binding fragment, further comprises a heavy chain having 95% sequence identity to SEQ ID NO: 9. 
     
     
         6 . The method of  claim 1 , wherein the antibody, or antigen binding fragment, further comprises a light chain having 95% sequence identity to SEQ ID NO: 10. 
     
     
         7 . The method of  claim 5 , wherein the antibody, or antigen binding fragment, further comprises a light chain having 95% sequence identity to SEQ ID NO: 10. 
     
     
         8 . The method of  claim 1 , wherein the subject is a human. 
     
     
         9 . A method of treating geographic atrophy comprising administering to a subject in need thereof an effective amount of a composition comprising an isolated antibody or antigen binding fragment thereof that specifically binds to a human complement C5 protein, said antibody or antigen binding fragment thereof comprising an HCDR1 sequence comprising the sequence of SEQ ID NO: 1, an HCDR2 sequence comprising the sequence of SEQ ID NO: 2, an HCDR3 sequence comprising the sequence of SEQ ID NO: 3, an LCDR1 sequence comprising the sequence of SEQ ID NO: 4, an LCDR2 sequence comprising the sequence of SEQ ID NO: 5, and an LCDR3 sequence comprising the sequence of SEQ ID NO: 6. 
     
     
         10 . The method of  claim 9 , wherein the antibody, or antigen binding fragment, further comprises a heavy chain variable region having 95% sequence identity to SEQ ID NO: 7. 
     
     
         11 . The method of  claim 9 , wherein the antibody, or antigen binding fragment, further comprises a light chain variable region having 95% sequence identity to SEQ ID NO: 8. 
     
     
         12 . The method of  claim 10 , wherein the antibody, or antigen binding fragment, further comprises a light chain variable region having 95% sequence identity to SEQ ID NO: 8. 
     
     
         13 . The method of  claim 9 , wherein the antibody, or antigen binding fragment, further comprises a heavy chain having 95% sequence identity to SEQ ID NO: 9. 
     
     
         14 . The method of  claim 9 , wherein the antibody, or antigen binding fragment, further comprises a light chain having 95% sequence identity to SEQ ID NO: 10. 
     
     
         15 . The method of  claim 13 , wherein the antibody, or antigen binding fragment, further comprises a light chain having 95% sequence identity to SEQ ID NO: 10. 
     
     
         16 . The method of  claim 9 , wherein the subject is a human.